All News Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-06-05 pm EDT			Pre-market 08:30:59 am
146 ^USD	-1.24%		146.5	+0.37%

11:20am	Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	MT
Jun. 05	J&J: applies to FDA for expanded indication for Prezcobix	CF

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	05:20am	MT
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	Jun. 05	AQ
J&J: applies to FDA for expanded indication for Prezcobix	Jun. 05	CF
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	Jun. 04	BU
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab	Jun. 04
J&J: successful trial for Carvykti in multiple myeloma	Jun. 04	CF
J&J: promising trial for Tecvayli in multiple myeloma	Jun. 04	CF
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	Jun. 04	PU
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	Jun. 04	MT
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	Jun. 04	AQ
J&J must pay $260 million in latest talc trial, Oregon jury says	Jun. 03	RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	Jun. 03	MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	Jun. 03	CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	Jun. 03	CI
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	Jun. 03	CI
Johnson & Johnson Completes Acquisition of Shockwave Medical	Jun. 03	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	Jun. 03	AQ
Johnson & Johnson Announces Longer-Term Data from the Pivotal Phase 1/2 Majestec-1 Study of TECVAYLI	Jun. 03	CI
J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO	Jun. 03	RE
J&J-backed Rapport Therapeutics seeks to raise $144 mln in US IPO	Jun. 03	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST